192 related articles for article (PubMed ID: 9110450)
1. [Treatment of chronic microvascular complications of diabetes mellitus with aldose reductase inhibitors].
Wajchenberg BL
Rev Assoc Med Bras (1992); 1996; 42(2):63-5. PubMed ID: 9110450
[No Abstract] [Full Text] [Related]
2. Aldose reductase inhibitors and the complications of diabetes mellitus.
Tomlinson DR
Diabet Med; 1993 Apr; 10(3):214-30. PubMed ID: 8485953
[No Abstract] [Full Text] [Related]
3. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
Cameron NE; Cotter MA; Basso M; Hohman TC
Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
[TBL] [Abstract][Full Text] [Related]
4. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
Cotter MA; Cameron NE; Hohman TC
J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of chronic complications of diabetes mellitus with aldose reductase inhibitors].
Cattalini M; Lerario AC
Rev Assoc Med Bras (1992); 1996; 42(2):109-14. PubMed ID: 9110460
[No Abstract] [Full Text] [Related]
6. [Clinical trial of the effects of isodibut on several indicators of microcirculation in combined therapy of patients with diabetes mellitus].
Kakhnovskiĭ IM; Koroleva TV; Golubiatnikova GA; Kalinkina MA
Klin Med (Mosk); 1996; 74(3):56-8. PubMed ID: 8926708
[TBL] [Abstract][Full Text] [Related]
7. [Role of aldose reductase inhibitors in the development of peripheral neuropathy in experimental diabetes].
Kuchmerovskaia TM; Donchenko GV; Klimenko AP; Chichkovskaia GV; Pakirbaeva LV; Kozitskiĭ ZIa; Efimov AS
Ukr Biokhim Zh (1978); 1997; 69(3):77-82. PubMed ID: 9505366
[TBL] [Abstract][Full Text] [Related]
8. Reduced nerve blood flow in diabetic rats: relationship to nitric oxide production and inhibition of aldose reductase.
Tomlinson DR; Dewhurst M; Stevens EJ; Omawari N; Carrington AL; Vo PA
Diabet Med; 1998 Jul; 15(7):579-85. PubMed ID: 9686698
[TBL] [Abstract][Full Text] [Related]
9. Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage.
Greene DA; Sima AA; Stevens MJ; Feldman EL; Killen PD; Henry DN; Thomas T; Dananberg J; Lattimer SA
Diabetes Metab Rev; 1993 Oct; 9(3):189-217. PubMed ID: 8187607
[No Abstract] [Full Text] [Related]
10. [Endothelial function and the microcirculation in diabetes mellitus].
Arosio E; Minuz P; Prior M
Ann Ital Med Int; 1999; 14(2):106-13. PubMed ID: 10399372
[TBL] [Abstract][Full Text] [Related]
11. Microvascular perfusion and transport in the diabetic heart.
McDonagh PF; Hokama JY
Microcirculation; 2000 Jun; 7(3):163-81. PubMed ID: 10901496
[TBL] [Abstract][Full Text] [Related]
12. An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.
Hara T; Nakamura J; Koh N; Sakakibara F; Hamada Y; Sasaki H; Naruse K; Nakashima E; Takeuchi N; Inukai S
J Lab Clin Med; 1995 Dec; 126(6):541-7. PubMed ID: 7490513
[TBL] [Abstract][Full Text] [Related]
13. Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
Maccari R; Ottanà R
J Med Chem; 2015 Mar; 58(5):2047-67. PubMed ID: 25375908
[TBL] [Abstract][Full Text] [Related]
14. The role of oxidative stress in diabetic vascular and neural disease.
Yorek MA
Free Radic Res; 2003 May; 37(5):471-80. PubMed ID: 12797466
[TBL] [Abstract][Full Text] [Related]
15. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
Hotta N; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K; Naruse K; Nakashima E; Sakamoto N
J Pharmacol Exp Ther; 1996 Jan; 276(1):49-55. PubMed ID: 8558455
[TBL] [Abstract][Full Text] [Related]
16. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ
FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499
[TBL] [Abstract][Full Text] [Related]
17. Aldose reductase in diabetic microvascular complications.
Chung SS; Chung SK
Curr Drug Targets; 2005 Jun; 6(4):475-86. PubMed ID: 16026266
[TBL] [Abstract][Full Text] [Related]
18. The role of free radicals, oxidative stress and antioxidant systems in diabetic vascular disease.
Jakus V
Bratisl Lek Listy; 2000; 101(10):541-51. PubMed ID: 11218944
[TBL] [Abstract][Full Text] [Related]
19. Effect of an aldose reductase inhibitor on abnormalities of electroretinogram and vascular factors in diabetic rats.
Hotta N; Koh N; Sakakibara F; Nakamura J; Hara T; Hamada Y; Fukasawa H; Kakuta H; Sakamoto N
Eur J Pharmacol; 1997 May; 326(1):45-51. PubMed ID: 9178654
[TBL] [Abstract][Full Text] [Related]
20. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
